Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | AHCY | P23526 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | AMD1 | P17707 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7680471 | 1.00 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL18009771 | 0.89 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13975991 | 0.85 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL6573811 | 0.85 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13966427 | 0.85 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL23080211 | 0.85 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL14075793 | 0.85 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL21139456 | 0.85 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL24600719 | 0.84 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL21367292 | 0.84 | PRMT5 (0.41) | ADORA3ADORA1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2023-06-08 | — | — | US | disclosed |
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2023-06-08 | — | — | US | disclosed |
| US-11524962-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210403472-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-12-30 | — | — | US | disclosed |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2018152548-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-08-23 | — | — | WO | disclosed |
| EP-3262057-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-1090019-B1 | ADENOSINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1447407-A1 | Adenosine derivatives | GLAXO GROUP LIMITED (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6677316-B2 | TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL | SMITHKLINE BEECHAM CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030096788-A1 | Adenosine derivatives | GLAXO WELLCOME INC. | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | PI4KA 769/4885PI4K2B 1095/4885PI4K2A 903/4885 |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PI4KA 2213/4885PI4K2B 2369/4885PI4K2A 2854/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PI4KA 989/4885PI4K2B 1184/4885PI4K2A 1232/4885 |
| US-20030096788-A1 | Adenosine derivatives | ADORA3, ADORA2A, ADORA1 | PI4KA 1727/4885PI4K2B 2708/4885PI4K2A 1729/4885 |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PI4KA 2334/4885PI4K2B 2479/4885PI4K2A 3021/4885 |
| US-20210403472-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PI4KA 3135/4885PI4K2B 3153/4885PI4K2A 3603/4885 |
| US-11524962-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) | PRMT5, PRMT1, PRMT3 | PI4KA 3193/4885PI4K2B 3007/4885PI4K2A 3513/4885 |
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRMT5, PRMT1, PRMT3 | PI4KA 3217/4885PI4K2B 3027/4885PI4K2A 3526/4885 |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PI4KA 2213/4885PI4K2B 2369/4885PI4K2A 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.